Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: regenerative therapeutics - Surrozen

Next Previous
Search
Drug Profile

Research programme: regenerative therapeutics - Surrozen

Latest Information Update: 28 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Surrozen
  • Class Anti-inflammatories; Antifibrotics; Bispecific antibodies; Eye disorder therapies; Hepatoprotectants; Osteoporosis therapies; Urologics
  • Mechanism of Action Wnt signalling pathway stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fracture; Idiopathic pulmonary fibrosis; Osteoporosis
  • Research Chronic obstructive pulmonary disease; Diabetic retinopathy; Dry age-related macular degeneration; Dry eyes; Focal segmental glomerulosclerosis; Fuchs' endothelial dystrophy; Limbal stem cell deficiency; Polycystic kidney disease; Short bowel syndrome; Sjogren's syndrome; Type 1 diabetes mellitus; Wet age-related macular degeneration; Wounds
  • No development reported Hearing loss; Inflammation; Liver disorders; Lung disorders; Neurodegenerative disorders

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for research development in Hearing loss in USA (Parenteral)
  • 28 Jun 2024 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
  • 28 Jun 2024 No recent reports of development identified for preclinical development in Lung-disorders in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top